Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

Even with Eli Lilly's Mounjaro and Zepbound not growing as fast as many ... analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... market will be worth $33.7 billion. The near-10% compound annual growth rate predicted by the ...

Zepbound (tirzepatide ... researchers found that tirzepatide in doses of 5, 10, and 15 milligrams (mg) resulted in significant and sustained weight loss. The study, which had support from the ...